1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1780200030

KEVIN A PATRIZIO OD
Prescription History 1780200030
Optometrist in New York, NY

NPI Status: Active since June 23, 2020

Contact Information

30 E 60TH ST RM 201
NEW YORK, NY
ZIP 10022
Phone: (212) 355-5145

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KEVIN A PATRIZIO OD, an active Optometrist specialist practicing in New York, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 66 documented patient claims. Among these therapy options, the most frequently utilized medication is Tobramycin-Dexamethasone, which accounts for 24 claims alone.

Medication Index

C
O
R
T
No matching medications currently found on file.

Cequa

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 29.5
Days Supply 885
NY State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills49.2
Peer Average Days Supply1,471
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.5% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,802.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,186.84

State Avg Cost Per Claim

$784.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Ofloxacin

Generic Formulation: OfloxacinSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 16.3
Days Supply 310
NY State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills78.4
Peer Average Days Supply1,731
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.5% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $370.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.68

State Avg Cost Per Claim

$20.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Therapeutic Applications

This medication is used to treat eye infections. Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 480
NY State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills145.4
Peer Average Days Supply4,333
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,242.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$936.84

State Avg Cost Per Claim

$1,034.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Tobramycin-Dexamethasone

Generic Formulation: Tobramycin/DexamethasoneSpecialty: Optometry
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.8
Days Supply 425
NY State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills44.2
Peer Average Days Supply853
Conservative Utilization

This provider writes prescriptions for this formulation 41.5% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,473.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.39

State Avg Cost Per Claim

$81.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.

Therapeutic Applications

This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KEVIN A PATRIZIO OD provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.